Nexthera Capital’s Stemline Therapeutics STML Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
– Sell
-325,526
Closed -$4.18M – 35
2019
Q1
$4.18M Sell
325,526
-386,032
-54% -$4.36M 5.08% 8
2018
Q4
$6.76M Buy
711,558
+129,488
+22% +$1.68M 2.79% 12
2018
Q3
$9.7M Buy
582,070
+22,553
+4% +$362K 1.85% 17
2018
Q2
$8.98M Buy
559,517
+35,893
+7% +$641K 1.39% 22
2018
Q1
$8.01M Buy
+523,624
New +$8.16M 1.32% 25

Other funds holding STML

Nexthera Capital's STML Position: Q2 2019 in Review

Nexthera Capital sold out of Stemline Therapeutics (STML) in Q2 2019, closing a stake of 325,526 shares — an estimated $4.18M sold.

Nexthera Capital first reported a position in STML in Q1 2018 and held it in 5 quarters. The position peaked at $9.7M in Q3 2018. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.

  • Nexthera Capital reported no remaining Stemline Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Nexthera Capital sold 325,526 Stemline Therapeutics shares in Q2 2019, an estimated $4.18M.
  • Nexthera Capital first reported a position in Stemline Therapeutics in Q1 2018 and held it in 5 quarters.
  • Nexthera Capital's Stemline Therapeutics position peaked at $9.7M in Q3 2018.
  • 96 funds tracked by Wall St. Rank held Stemline Therapeutics as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.